PARIS--(BUSINESS WIRE)--Sorin Group (MIL:SRN) Cardiac Rhythm Management (CRM) Business Unit today announced the initiation of the OPTION (Optimal Antitachycardia Therapy in ICD Patients without Pacing Indication) clinical study in Europe. The primary objective of the study is to demonstrate that implantable dual chamber cardioverter defibrillators (ICDs) have greater efficacy than single chamber ICDs in reducing inappropriate shock delivery and have the same efficacy in reducing all cause patient mortality and hospitalizations due to cardiovascular events.
